These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23358123)

  • 41. The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
    Wang J; Jin X; An P; Yu S; Mu Y
    J Diabetes Res; 2019; 2019():8083417. PubMed ID: 31772945
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications.
    Heile M; Wyne K; Billings LK; Cannon A; Handelsman Y; Shannon M
    J Manag Care Spec Pharm; 2018 Sep; 24(9-a Suppl):S42-S52. PubMed ID: 30156446
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity.
    Coveleskie K; Kilpatrick LA; Gupta A; Stains J; Connolly L; Labus JS; Sanmiguel C; Mayer EA
    Obes Sci Pract; 2017 Dec; 3(4):434-445. PubMed ID: 29259802
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes.
    Genovese S; Mannucci E; Ceriello A
    Adv Ther; 2017 Aug; 34(8):1791-1814. PubMed ID: 28674957
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists.
    Courtney H; Nayar R; Rajeswaran C; Jandhyala R
    Diabetes Metab Syndr Obes; 2017; 10():79-87. PubMed ID: 28331351
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study.
    Henry RR; Klein EJ; Han J; Iqbal N
    Diabetes Technol Ther; 2016 Nov; 18(11):677-686. PubMed ID: 27525540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists.
    Kang YM; Jung CH
    Endocrinol Metab (Seoul); 2016 Jun; 31(2):258-74. PubMed ID: 27118277
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.
    Peng H; Want LL; Aroda VR
    Curr Diab Rep; 2016 May; 16(5):44. PubMed ID: 27037706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
    Simó R; Guerci B; Schernthaner G; Gallwitz B; Rosas-Guzmàn J; Dotta F; Festa A; Zhou M; Kiljański J
    Cardiovasc Diabetol; 2015 Sep; 14():116. PubMed ID: 26338040
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance.
    Tella SH; Rendell MS
    Ther Adv Endocrinol Metab; 2015 Jun; 6(3):109-34. PubMed ID: 26137215
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.
    Syed YY; McCormack PL
    Drugs; 2015 Jul; 75(10):1141-52. PubMed ID: 26071140
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mitigating the Burden of Type 2 Diabetes: Challenges and Opportunities.
    Am Health Drug Benefits; 2015 Apr; 8(2 Suppl 1):S3-S11. PubMed ID: 26064434
    [No Abstract]   [Full Text] [Related]  

  • 53. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.
    MacConell L; Gurney K; Malloy J; Zhou M; Kolterman O
    Diabetes Metab Syndr Obes; 2015; 8():241-53. PubMed ID: 26056482
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.
    Weinstock RS; Guerci B; Umpierrez G; Nauck MA; Skrivanek Z; Milicevic Z
    Diabetes Obes Metab; 2015 Sep; 17(9):849-58. PubMed ID: 25912221
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes.
    LaRue S; Malloy J
    J Diabetes Sci Technol; 2015 Jul; 9(4):815-21. PubMed ID: 25759181
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus.
    Harris KB; McCarty DJ
    Ther Adv Endocrinol Metab; 2015 Feb; 6(1):3-18. PubMed ID: 25678952
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of GLP-1 on appetite and weight.
    Shah M; Vella A
    Rev Endocr Metab Disord; 2014 Sep; 15(3):181-7. PubMed ID: 24811133
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of pancreatic β-cell function: review of methods and clinical applications.
    Cersosimo E; Solis-Herrera C; Trautmann ME; Malloy J; Triplitt CL
    Curr Diabetes Rev; 2014 Jan; 10(1):2-42. PubMed ID: 24524730
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus.
    Cho YM; Wideman RD; Kieffer TJ
    Endocrinol Metab (Seoul); 2013 Dec; 28(4):262-74. PubMed ID: 24396690
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Guideline approach to therapy in patients with newly diagnosed type 2 diabetes.
    Raz I
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S139-44. PubMed ID: 23882038
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.